Fortfahren mit
SML0218
Bropirimine
≥98% (HPLC)
Synonym(e):
2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone, NSC 149027, PNU 54461, U 54461, U 54461S
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Packungsgröße | SKU | Verfügbarkeit | Preis |
|---|
Über diesen Artikel
Empirische Formel (Hill-System):
C10H8BrN3O
CAS-Nummer:
Molekulargewicht:
266.09
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥5 mg/mL (warm DMSO)
storage temp.
room temp
SMILES string
NC1=NC(=O)C(Br)=C(N1)c2ccccc2
InChI
1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
InChI key
CIUUIPMOFZIWIZ-UHFFFAOYSA-N
Application
Bropirimine, an immunostimulating agent and toll like receptor (TLR7) agonist, is used in comparison with other TLR7 agonists such as imiquimod, R-848, loxoribine in interferon cell signaling research.[1] Bropirimine may be used in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research.[2]
Biochem/physiol Actions
Bropirimine is an immunostimulant, anti-tumor agent
Bropirimine is an immunostimulating agent. The compound induces production of α and β interferons and enhances NK cell function. Bropirimine has antiproliferative effects in cancer cell lines and tumor growth in in vivo models.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
M Shaw et al.
Methods and findings in experimental and clinical pharmacology, 20(2), 111-114 (1998-05-30)
Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression
M A Wynalda et al.
Xenobiotica; the fate of foreign compounds in biological systems, 33(10), 999-1011 (2003-10-14)
1. The antitumour agent bropirimine undergoes significant Phase II conjugation in vivo. Incubation of [14C]bropirimine with human liver microsomes resulted in the formation of a single product peak (M1) using high-performance liquid chromatography with radiochemical detection and was tentatively assigned
Sandra Demaria et al.
Oncoimmunology, 2(10), e25997-e25997 (2014-01-10)
Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML0218-50MG | 04061832260815 |
| SML0218-10MG | 04061832633107 |